Remus Pharmaceuticals Ltd Stock Price Today (NSE: REMUS)
Fundamental Score
Remus Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Remus Pharmaceuticals Ltd share price today is ₹705.45, up +0.00% on NSE/BSE as of 19 February 2026. Remus Pharmaceuticals Ltd (REMUS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹840.73 (Cr). The 52-week high for REMUS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 25.09x, REMUS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 14.00% and a debt-to-equity ratio of 0.05.
Remus Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Remus Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Remus Pharmaceuticals Share Price: Financial Stability Analysis
A unique insight into the pharmaceutical industry is the substantial investment required in research and development, creating barriers to entry and impacting long-term profitability. This analysis examines the financial stability of Remus Pharmaceuticals Ltd, focusing on its current valuation and key performance indicators. Presently, the Remus Pharmaceuticals share price stands at ₹657.0, with a Price-to-Earnings (PE) ratio of 25.09. This valuation needs careful consideration relative to its peers and future growth prospects.
Remus Pharmaceuticals Ltd's Return on Capital Employed (ROCE) is 19.64%. A high ROCE like this suggests efficient capital allocation and strong profitability. This robust ROCE contributes to the company's economic moat by allowing it to reinvest profits at a high rate of return, potentially leading to a sustainable competitive advantage and long-term value creation. This level of return indicates that for every rupee invested in the business, Remus Pharmaceuticals is generating nearly 20 paisa of profit, a favorable sign for investors.
When evaluating Remus Pharmaceuticals, it is useful to consider its position compared to sector peers. For example,
Mankind Pharma Ltd is perceived to have higher management quality, potentially leading to better strategic decisions and operational efficiency. While Mankind Pharma is a larger and more established company, it is important to evaluate if Remus Pharmaceuticals’ growth rate can justify its current valuation. Similarly, understanding the operational scale and market reach of Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd is essential for a comprehensive comparative analysis.This assessment is part of a comprehensive 80-parameter fundamental audit, a structured framework designed to evaluate various aspects of the company's financial health and performance, verified by Sweta Mishra. This analysis is purely observational and does not constitute financial advice. Investors should conduct their own independent research and consult with a qualified financial advisor before making any investment decisions regarding Remus Pharmaceuticals Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Remus Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of REMUS across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (19.64%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 25.09 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (24.91%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (46.77%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.05)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (42.28x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (70.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 5.79%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Remus Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Remus Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About REMUS (Remus Pharmaceuticals Ltd)
Remus Pharmaceuticals Ltd (REMUS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹840.73 (Cr). Remus Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 14.00% and a ROCE of 19.64%. The debt-to-equity ratio stands at 0.05, reflecting the company's capital structure. Investors tracking REMUS share price can monitor key metrics including P/E ratio, promoter holding of 70.91%, and quarterly earnings growth.
Company Details
REMUS Share Price: Frequently Asked Questions
What is the current share price of Remus Pharmaceuticals Ltd (REMUS)?
As of 19 Feb 2026, 10:19 am IST, Remus Pharmaceuticals Ltd share price is ₹705.45. The REMUS stock has a market capitalisation of ₹840.73 (Cr) on NSE/BSE.
Is REMUS share price Overvalued or Undervalued?
REMUS share price is currently trading at a P/E ratio of 25.09x, compared to the industry average of 31.77x. Based on this relative valuation, the Remus Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of REMUS share price?
The 52-week high of REMUS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Remus Pharmaceuticals Ltd share price?
Key factors influencing REMUS share price include quarterly earnings growth (Sales Growth: 46.77%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Remus Pharmaceuticals Ltd a good stock for long-term investment?
Remus Pharmaceuticals Ltd shows a 5-year Profit Growth of N/A% and an ROE of 14.00%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.05 before investing in REMUS shares.
How does Remus Pharmaceuticals Ltd compare with its industry peers?
Remus Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare REMUS share price P/E of 25.09x and ROE of 14.00% against the industry averages to determine competitive standing.
What is the P/E ratio of REMUS and what does it mean?
REMUS share price has a P/E ratio of 25.09x compared to the industry average of 31.77x. Investors pay ₹25 for every ₹1 of annual earnings.
How is REMUS performing according to Bull Run's analysis?
REMUS has a Bull Run fundamental score of 46.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does REMUS belong to?
REMUS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Remus Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for REMUS?
REMUS has an ROE of 14.00%, which shows decent profitability but room for improvement. ROE measures how efficiently Remus Pharmaceuticals Ltd generates profits from shareholders capital.
How is REMUS debt-to-equity ratio and what does it indicate?
REMUS has a debt-to-equity ratio of 0.05, which indicates conservative financing with low financial risk.
What is REMUS dividend yield and is it a good dividend stock?
REMUS offers a dividend yield of 0.14%, meaning you receive ₹0.14 annual dividend for every ₹100 invested in Remus Pharmaceuticals Ltd shares.
How has REMUS share price grown over the past 5 years?
REMUS has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in REMUS and why does it matter?
Promoters hold 70.91% of REMUS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Remus Pharmaceuticals Ltd.
What is REMUS market capitalisation category?
REMUS has a market capitalisation of ₹841 crores, placing it in the Small-cap category.
How volatile is REMUS stock?
REMUS has a beta of N/A. A beta > 1 suggests the Remus Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is REMUS operating profit margin trend?
REMUS has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is REMUS quarterly performance?
Recent quarterly performance shows Remus Pharmaceuticals Ltd YoY Sales Growth of 46.77% and YoY Profit Growth of 24.91%.
What is the institutional holding pattern in REMUS?
REMUS has FII holding of 5.02% and DII holding of 0.77%. Significant institutional holding often suggests professional confidence in the Remus Pharmaceuticals Ltd stock.